Mutant p53 initiates a feedback loop that involves Egr-1/EGF receptor/ERK in prostate cancer cells

Oncogene

Volumn 29, Issue 18, 2010, Pages 2628-2637

  Sauer, L ^a,b   Gitenay, D ^a,c   Vo, C ^a   Baron, V T ^a  

^a Vaccine Research Institute of San Diego   (United States)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c CENTRE LÉON BÉRARD   (France)

Author keywords

EGF receptor; Egr 1; P53; Prostate cancer; SV40 large T antigen

Indexed keywords

AMPHIREGULIN; CYTOKINE; EARLY GROWTH RESPONSE FACTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIREGULIN; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN P53; VIRUS LARGE T ANTIGEN;

ARTICLE; CANCER CELL; CANCER GROWTH; CONTROLLED STUDY; FEEDBACK SYSTEM; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; RNA INTERFERENCE;

CELL LINE, TUMOR; EARLY GROWTH RESPONSE PROTEIN 1; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEEDBACK, PHYSIOLOGICAL; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MUTATION; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77952236403     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.24     Document Type: Article

References (40)

1. Abdulkadir SA, Qu Z, Garabedian E, Song SK, Peters TJ, Svaren J et al. (2001). Impaired prostate tumorigenesis in Egr1-deficient mice. Nat Med 7: 101-107.
2. Bae VL, Jackson-Cook CK, Brothman AR, Maygarden SJ, sWare JL. (1994). Tumorigenicity of SV40 T antigen immortalized human prostate epithelial cells: association with decreased epidermal growth factor receptor (EGFR) expression. Int J Cancer 58: 721-729.
3. Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B. (1990). Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249: 912-915.
4. Baron V, De Gregorio G, Krones-Herzig A, Virolle T, Calogero A, Urcis R et al. (2003). Inhibition of Egr-1 expression reverses transformation of prostate cancer cells in vitro and in vivo. Oncogene 22: 4194-4204.
5. Bello D, Webber MM, Kleinman HK, Wartinger DD, Rhim JS. (1997). Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis 18: 1215-1223.
6. Biswas S, Criswell TL, Wang SE, Arteaga CL. (2006). Inhibition of transforming growth factor-beta signaling in human cancer: targeting a tumor suppressor network as a therapeutic strategy. Clin Cancer Res 12: 4142-4146.
7. Bocchetta M, Eliasz S, De Marco MA, Rudzinski J, Zhang L, Carbone M. (2008). The SV40 large T antigen-p53 complexes bind and activate the insulin-like growth factor-I promoter stimulating cell growth. Cancer Res 68: 1022-1029.
8. Cao X, Mahendran R, Guy GR, Tan YH. (1993). Detection and characterization of cellular EGR-1 binding to its recognition site. J Biol Chem 268: 16949-16957.
9. Connolly JM, Rose DP. (1991). Autocrine regulation of DU145 human prostate cancer cell growth by epidermal growth factor-related polypeptides. Prostate 19: 173-180.
10. Deb SP, Munoz RM, Brown DR, Subler MA, Deb S. (1994). Wild-type human p53 activates the human epidermal growth factor receptor promoter. Oncogene 9: 1341-1349.
11. Deffie A, Wu H, Reinke V, Lozano G. (1993). The tumor suppressor p53 regulates its own transcription. Mol Cell Biol 13: 3415-3423.
12. Eid MA, Kumar MV, Iczkowski KA, Bostwick DG, Tindall DJ. (1998). Expression of early growth response genes in human prostate cancer. Cancer Res 58: 2461-2468.
13. Gitenay D, Baron VT. (2009). Is EGR1 a potential target for prostate cancer therapy? Future Oncol 5: 993-1003.
14. Gurova KV, Rokhlin OW, Budanov AV, Burdelya LG, Chumakov PM, Cohen MB et al. (2003). Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells. Cancer Res 63: 2905-2912.
15. Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, Friedman M, Papsidero L et al. (1980). The LNCaP cell line-a new model for studies on human prostatic carcinoma. Prog Clin Biol Res 37: 115-132.
16. Isaacs WB, Carter BS, Ewing CM. (1991). Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 51: 4716-4720.
17. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. (2007). Cancer statistics, 2007. CA Cancer J Clin 57: 43-66.
18. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. (1979). Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17: 16-23.
19. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV et al. (1999). A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285: 1733-1737.
20. Lilyestrom W, Klein MG, Zhang R, Joachimiak A, Chen XS. (2006). Crystal structure of SV40 large T-antigen bound to p53: interplay between a viral oncoprotein and a cellular tumor suppressor. Genes Dev 20: 2373-2382.
21. Long SB, Ho HY, Chen CL, Lai MD. (1995). Complex of simian virus large T antigen and p53 can bind DNA specifically. Anticancer Res 15: 1375-1380.
22. Ludes-Meyers JH, Subler MA, Shivakumar CV, Munoz RM, Jiang P, Bigger JE et al. (1996). Transcriptional activation of the human epidermal growth factor receptor promoter by human p53. Mol Cell Biol 16: 6009-9019.
23. Nishi H, Nishi KH, Johnson AC. (2002). Early growth response-1 gene mediates up-regulation of epidermal growth factor receptor expression during hypoxia. Cancer Res 62: 827-834.
24. Parda DS, Thraves PJ, Kuettel MR, Lee MS, Arnstein P, Kaighn ME et al. (1993). Neoplastic transformation of a human prostate epithelial cell line by the v-Ki-ras oncogene. Prostate 23: 91-98. (Pubitemid 23289890)
25. Ramsamooj P, Kuettel M, Dritschilo A, Jung M. (1997). p53-Independent tumorigenic progression of human prostate cells. Radiat Oncol Investig 5: 269-274.
26. Shin SY, Bahk YY, Ko J, Chung IY, Lee YS, Downward J et al. (2006). Suppression of Egr-1 transcription through targeting of the serum response factor by oncogenic H-Ras. EMBO J 25: 1093-1103.
27. Silverman ES, Collins T. (1999). Pathways of Egr-1-mediated gene transcription in vascular biology. Am J Pathol 154: 665-670.
28. Sramkoski RM, Pretlow 2nd TG, Giaconia JM, Pretlow TP, Schwartz S, Sy MS et al. (1999). A new human prostate carcinoma cell line 22Rv1 in vitro. Cell Dev Biol Anim 35: 403-409.
29. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. (1978). Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 21: 274-281.
30. Svaren J, Ehrig T, Abdulkadir SA, Ehrengruber MU, Watson MA, Milbrandt J. (2000). EGR1 target genes in prostate carcinoma cells identified by microarray analysis. J Biol Chem 275: 38524-38531.
31. Teicher BA. (2007). Transforming growth factor-beta and the immune response to malignant disease. Clin Cancer Res 13: 6247-6251.
32. Thiel G, Cibelli G. (2002). Regulation of life and death by the zinc finger transcription factor Egr-1. J Cell Physiol 193: 287-292.
33. Thigpen AE, Cala KM, Guileyardo JM, Molberg KH, McConnell JD, Russell DW. (1996). Increased expression of early growth response-1 messenger ribonucleic acid in prostatic adenocarcinoma. J Urol 155: 975-981.
34. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. (2004). in vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844-848.
35. Virolle T, Krones-Herzig A, Baron V, De Gregorio G, Adamson ED, Mercola D. (2003). Egr1 promotes growth and survival of prostate cancer cells. Identification of novel Egr1 target genes. J Biol Chem 278: 11802-11810.
36. Weisz L, Zalcenstein A, Stambolsky P, Cohen Y, Goldfinger N, Oren M et al. (2004). Transactivation of the EGR1 gene contributes to mutant p53 gain of function. Cancer Res 64: 8318-8327.
37. Wrzesinski SH, Wan YY, Flavell RA. (2007). Transforming growth factor-beta and the immune response: implications for anticancer therapy. Clin Cancer Res 13: 5262-5270.
38. Wu GS. (2004). The functional interactions between the p53 and MAPK signaling pathways. Cancer Biol Ther 3: 156-161.
39. Yang SZ, Abdulkadir SA. (2003). Early growth response gene 1 modulates androgen receptor signaling in prostate carcinoma cells. J Biol Chem 278: 39906-39911.
40. Yu J, Baron V, Mercola D, Mustelin T, Adamson ED. (2007). A network of p73, p53 and Egr1 is required for efficient apoptosis in tumor cells. Cell Death Differ 14: 436-446.